Study for Predictors of Effectiveness in Tocilizumab Therapy (PETITE)
Phase 4
- Conditions
- rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000002246
- Lead Sponsor
- Osaka City University Medical School, Center for Senile Degerative Disorders (CSDD)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who received tocilizumab therapy previously Patients who received steroid newly, dose-up of steroid, plasma exchange or artificial joint replacements within 4 weeks before tocilizumab treatment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method